NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396

1.1 Trametinib in combination with dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes.

https://www.nice.org.uk/guidance/ta396

Site by Devopa
© Copyright 2019 NHS. All rights reserved.